Herantis Pharma Oyj Logo

Herantis Pharma Oyj

Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.

HRTIS | ST

Overview

Corporate Details

ISIN(s):
FI4000087861
LEI:
743700W4CQVYAT3WKK38
Country:
Finland
Address:
Bertel Jungin Aukio 1, FI-02600 ESPOO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Herantis Pharma is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative conditions, with a primary emphasis on Parkinson's disease. The company's mission is to address significant unmet medical needs by creating treatments designed to stop or reverse disease progression. Its research and development efforts are centered on its proprietary technology platform, which includes lead drug candidates like HER-096, a therapy based on the Cerebral Dopamine Neurotrophic Factor (CDNF) protein.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Herantis Pharma Oyj filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Herantis Pharma Oyj

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Herantis Pharma Oyj via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea
196170
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America
ATHE
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America
ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America
ALMS
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America
ALZN
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden
ALZ
AMARIN CORP PLC\UK Logo
Develops prescription therapies like Vascepa® to reduce cardiovascular risk for patients.
United States of America
AMRN
AMGEN INC Logo
Biotech pioneer developing innovative human therapeutics for the world's toughest diseases.
United States of America
AMGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.